Rights issue in IBT fully subscribed – BioGaia’s underwriting guarantee will not be utilized
27th April the market was informed that BioGaia guaranteed the issue in the former subsidiary IBT up to an amount of SEK 38 million.
Today it was announced that the rights issue in IBT was fully subscribed. Hence, the underwriting guarantee will not be utilized.
Latest press releases from BioGaia
2017-05-17 BioGaia’s probiotic effective in treating abdominal pain in children
2016-05-11 Annual General Meeting of BioGaia
2016-05-10 BioGaia AB – Interim management statement 1 January - 31 March 2016
BioGaia has published this information in accordance with the Swedish Securities Act. The information was issued for publication on 26 May 2016, 8:30 am CET.
For additional information please contact
Axel Sjöblad, Managing Director, BioGaia: +46 8 555 293 00
BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri which has probiotic, health- enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of the Nasdaq OMX Nordic Exchange Stockholm. www.biogaia.com.
BioGaia AB Box 3242. SE-103 64 STOCKHOLM Street address: Kungsbroplan 3A, Stockholm Telephone: +46 8 555 293 00, Corp. identity no. 556380-8723. www.biogaia.com.